Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Harvest Technologies Corp.

This article was originally published in Start Up

Executive Summary

Harvest is building upon the autotransfusion concept to create devices which not only have the capacity to collect a patient's blood just prior to and during surgery, but which can also convert collected blood into autologous blood products that promote post-surgical wound healing, bone growth and hemostasis.

You may also be interested in...



Harvest Steps into Stem Cells

Harvest Technologies, a 14-year-old player in the blood and marrow supply arena, is moving aggressively into the business of selling stem cells therapies for cardiovascular disease.

Lilly Signs Deals With Dexcom, Glooko, myDiabby, Roche For Diabetes Management Solutions

Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037050

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel